Application of intravenous umbilical cord blood mononuclear cells in treatment of end stage heart failure
10.3969/j.issn.1009-0126.2018.04.012
- VernacularTitle:脐血单个核细胞经静脉途径治疗终末期心力衰竭的研究
- Author:
Dongxue GAO
1
;
Yanhua LIU
;
Tian WANG
Author Information
1. 山东省立第三医院心内科
- Keywords:
fetal blood;
monocytes;
heart failure;
stem cell transplantation
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2018;20(4):382-384
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the safety and efficacy of intravenous umbilical cord blood mononuclear cells in treatment of end stage heart failure (HF).Methods Twenty-one end stage HF patients with cardiac function Ⅳaccording to NYHA were treated with intravenous umbilical cord blood mononuclear cells.Their cardiac function was assessed,their NT-proBNP,LVEF,LVEDD were measured before and after treatment for 1 month,3 months and 6 months.Results Umbilical cord blood mononuclear cells were effective for 20 patients and ineffective for 1 patient who died within 30 days after treatment.The rate of improved cardiac function Ⅱ and Ⅲ was significantly higher while the serum NT-proBNP level was significantly lower after treatment for 1 month and 3 months (90.5％,95.2％ vs 0％,P＜0.05;3045.3±103.8 ng/L,3367.5±111.4 ng/L vs 5312.1±121.9 ng/L,P＜0.05).Conclusion Intravenous umbilical cord blood mononuclear cells are safe for end stage HF patients,alleviate their symptoms,improve their cardiac function and quality of life with no significant side effect.
